Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rui Therapeutics

Request full access

Next-generation cell therapies for autoimmune and inflammatory diseases

Nanjing City, ChinaFounded 2021Biotech & Life Sciences

About Rui Therapeutics

Rui Therapeutics, established in June 2021, is a clinical-stage biopharmaceutical company focused on developing new drugs based on next-generation cell therapies. The company was co-founded by Dr. Qian Hao, who serves as CEO, alongside other overseas scientists and executives from multinational pharmaceutical firms. Their mission is to create innovative treatments using core technologies with independent intellectual property rights.

The firm has established three main technology platforms: a CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy platform, a therapeutic single-base gene editing platform, and a small molecule-induced regenerative medicine platform. Rui Therapeutics has developed proprietary technologies such as the HTAS-RV™ viral delivery system and CRA-NKTM taming technology. Its primary focus is on developing first-in-class pipeline products for indications with significant unmet clinical needs, including autoimmune diseases, tumors, inflammatory diseases, central nervous system disorders, and anti-aging.

Rui Therapeutics' lead candidate, KN5501, is a CAR-NK cell therapy for Systemic Lupus Erythematosus (SLE) that received IND approval in China in September 2025. In collaboration with Shanghai Changhai Hospital, early clinical data from researcher-initiated trials (IIT) for KN5501 has demonstrated good efficacy and safety in treating severe SLE patients. The company's pipeline also includes treatments for other autoimmune conditions and various cancers, with several products in IIT clinical trials.

The company has secured significant funding to advance its pipeline. In July 2023, it completed a Pre-A financing round of tens of millions of RMB. More recently, in September 2025, Rui Therapeutics announced a Series A financing round exceeding CNY 200 million, co-led by several prominent venture capital firms. This capital is being used to support IND submissions, advance pipeline products, and expand research and development efforts.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Autoimmune, Inflammatory Diseases, Cell Therapy, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2025 $28M $110M Nanshan Strategic Emerging · Shenzhen Capital Group · Wanbang Pharmaceutical Technology · Nanshan Venture Capital ↗
SEED✓Equity / VC Jul 2023 $2.8M $11M Undisclosed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rui Therapeutics website traffic

Latest recorded traffic for Rui Therapeutics is 140 monthly website visits, down 30% over the last three months.

Latest monthly visits140 3-month web change-30%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rui Therapeutics in the Nanjing City ecosystem

Live from Dealroom

The Rui Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Shenzhen Capital Group
  • Green Pine Capital
  • Nanshan Strategic Emerging
  • Wanbang Pharmaceutical Technology
  • Nanshan Venture Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Nanjing City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rui Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rui Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.